STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACAD
  4. [Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

Acadia (ACAD) CFO receives new stock options and RSU awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC reported that EVP and Chief Financial Officer Mark C. Schneyer received new equity awards. He was granted stock options for 90,691 shares of common stock at an exercise price of $22.16 per share, expiring on March 5, 2036. According to the terms, 25% of these options vest and become exercisable on March 6, 2027, with the remaining options vesting in 36 equal monthly installments thereafter.

Schneyer was also granted 26,382 restricted stock units, each representing a contingent right to receive one share of common stock. These restricted stock units vest in four equal annual installments beginning on March 6, 2027. All transactions are classified as awards or grants rather than open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Schneyer Mark C.
Role EVP, CHIEF FINANCIAL OFFICER
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 90,691 $0.00 $0.00
Grant/Award Restricted Stock Units 26,382 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 90,691 shares (Direct); Restricted Stock Units — 26,382 shares (Direct)
Footnotes (3)
  1. F1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
  3. F3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.

FAQ

What equity awards did ACAD (ACAD) grant to CFO Mark C. Schneyer?
ACAD granted Mark C. Schneyer stock options for 90,691 shares and 26,382 restricted stock units. Both awards provide future rights to common stock, subject to multi-year vesting schedules starting in March 2027.

What are the key terms of Mark Schneyer’s new stock options at ACAD?
Schneyer received options for 90,691 shares at an exercise price of $22.16 per share, expiring on March 5, 2036. Twenty-five percent vest on March 6, 2027, with the remaining options vesting in 36 equal monthly installments.

How do the restricted stock units for ACAD’s CFO vest over time?
The 26,382 restricted stock units granted to ACAD’s CFO vest in four equal annual installments. Vesting begins on March 6, 2027, and each unit represents a contingent right to receive one share of common stock upon vesting.

Were there any open-market stock purchases or sales in this ACAD Form 4?
No open-market purchases or sales are reported. The Form 4 shows grant or award acquisitions of stock options and restricted stock units, which are compensation-related equity awards rather than market trades in ACAD common stock.

What does the Form 4 reveal about ACAD’s use of equity compensation for executives?
The filing shows ACAD using stock options and restricted stock units to compensate its CFO. These awards vest over several years starting in 2027, aligning executive incentives with longer-term company performance and share value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schneyer Mark C.
(Last) (First) (Middle)
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
(Street)
SAN DIEGO CA 92130
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $22.16 03/06/2026 A 90,691 (1) 03/05/2036 Common Stock 90,691 $0 90,691 D
Restricted Stock Units (2) 03/06/2026 A 26,382 (3) (3) Common Stock 26,382 $0 26,382 D
Explanation of Responses:
1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.
/s/ Jennifer J. Rhodes, Attorney-in-Fact 03/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR